GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases. It is based on...
4 KB (202 words) - 14:35, 24 August 2023
GRAd-COV2 – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Archived from the original on 10 May 2021. Retrieved 8 May 2021. "ReiThera GRAd-COV2...
198 KB (13,219 words) - 00:29, 16 August 2024
biotech company ReiThera to test a COVID-19 vaccine candidate called GRAd-COV2, which is based on a modified gorilla adenovirus vector. "Nurse in Italy...
2 KB (222 words) - 12:29, 17 April 2023
October 2021. "GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. 27 August 2020. NCT04528641. "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine...
95 KB (18,965 words) - 23:35, 15 September 2024
Phase I Phase II Phase III Novavax Subunit Completed Completed Completed GRAd-COV2 Viral vector Completed Completed In progress Patria Viral vector Completed...
16 KB (1,162 words) - 20:33, 16 May 2024
Vaccine Type (technology) Phase I Phase II Phase III GRAd-COV2 Viral vector Completed Completed In progress COVID-eVax DNA In progress In progress Not...
57 KB (3,437 words) - 04:40, 3 August 2024
Biotech Viral vector AdCLD-CoV19 BriLife COH04S1 DelNS1-2019-nCoV-RBD-OPT GRAd-COV2 ImmunityBio iNCOVACC INNA-051 NDV-HXP-S Vaxart COVID-19 vaccine Virus-like...
180 KB (23,898 words) - 14:59, 19 August 2024
source and freely available to the public. The DNA vaccine expressed the SARS-CoV2 spike protein once inside human cells to elicit an immune response. She measured...
25 KB (2,005 words) - 20:40, 22 May 2024